Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein

Journal of Lipid Research

Volumn 56, Issue 5, 2015, Pages 972-985

  Luthi, Andrea J ^a   Lyssenko, Nicholas N ^c,d   Quach, Duyen ^c,d   McMahon, Kaylin M ^a,e   Millar, John S ^d   Vickers, Kasey C ^f   Rader, Daniel J ^a   Phillips, Michael C ^c,d   Mirkin, Chad A ^a,b   Thaxton, C Shad ^a,b,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; ATP binding cassette transporter G1; Cholesterol efflux; Macrophages; Scavenger receptor class B type I; Supplementary ATP binding cassette transporter A1

Indexed keywords

ABC TRANSPORTER G1; APOLIPOPROTEIN A1; GOLD NANOPARTICLE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ABC TRANSPORTER; ABC TRANSPORTER A1; ABCA1 PROTEIN, MOUSE; ABCG1 PROTEIN, MOUSE; CARDIOTONIC AGENT; CHOLESTEROL; GOLD; LIPOPROTEIN; NANOPARTICLE; PHOSPHOLIPID; SCARB1 PROTEIN, MOUSE; SCAVENGER RECEPTOR B;

ACTIVE TRANSPORT; ARTICLE; CELL LINE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIFFUSION; MACROPHAGE; PASSIVE TRANSPORT; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; ANIMAL; CORONARY ARTERY DISEASE; DRUG STABILITY; HAMSTER; METABOLISM; MOLECULAR MIMICRY; PRECLINICAL STUDY; SECRETION (PROCESS); TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; APOLIPOPROTEIN A-I; ATP BINDING CASSETTE TRANSPORTER 1; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 1; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARDIOTONIC AGENTS; CELL LINE; CHOLESTEROL; CORONARY ARTERY DISEASE; CRICETINAE; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; GOLD; LIPOPROTEINS; MACROPHAGES; MOLECULAR MIMICRY; NANOPARTICLES; PHOSPHOLIPIDS; SCAVENGER RECEPTORS, CLASS B;

EID: 84929406570     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M054635     Document Type: Article

References (58)

1. Lüscher, T. F., U. Landmesser, A. von Eckardstein, and A. M. Fogelman. 2014. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ. Res. 114: 171-182.
2. Miller, G. J., and N. E. Miller. 1975. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1: 16-19.
3. van Capelleveen, J. C., A. E. Bochem, M. M. Motazacker, G. K. Hovingh, and J. J. Kastelein. 2013. Genetics of HDL-C: a causal link to atherosclerosis? Curr. Atheroscler. Rep. 15: 326.
4. Wright, R. S. 2013. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol. Curr. Opin. Cardiol. 28: 389-398.
5. Rosenson, R. S., H. B. Brewer, Jr., W. S. Davidson, Z. A. Fayad, V. Fuster, J. Goldstein, M. Hellerstein, X. C. Jiang, M. C. Phillips, D. J. Rader, et al. 2012. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125: 1905-1919.
6. Westerterp, M., A. E. Bochem, L. Yvan-Charvet, A. J. Murphy, N. Wang, and A. R. Tall. 2014. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 114: 157-170.
7. de la Llera Moya, M., V. Atger, J. L. Paul, N. Fournier, N. Moatti, P. Giral, K. E. Friday, and G. Rothblat. 1994. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler. Thromb. 14: 1056-1065.
8. Weibel, G. L., D. Drazul-Schrader, D. K. Shivers, A. N. Wade, G. H. Rothblat, M. P. Reilly, and M. de la Llera-Moya. 2014. Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 34: 17-25.
9. de la Llera-Moya, M., D. Drazul-Schrader, B. F. Asztalos, M. Cuchel, D. J. Rader, and G. H. Rothblat. 2010. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 30: 796-801.
10. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
11. Hafiane, A., B. Jabor, I. Ruel, J. Ling, and J. Genest. 2014. Highdensity lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. Am. J. Cardiol. 113: 249-255.
12. Doonan, R. J., A. Hafiane, C. Lai, J. P. Veinot, J. Genest, and S. S. Daskalopoulou. 2014. Cholesterol efflux capacity, carotid atherosclerosis, and cerebrovascular symptomatology. Arterioscler. Thromb. Vasc. Biol. 34: 921-926.
13. Kingwell, B. A., and M. J. Chapman. 2013. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease. Circulation. 128: 1112-1121.
14. van Capelleveen, J. C., H. B. Brewer, J. J. Kastelein, and G. K. Hovingh. 2014. Novel therapies focused on the high-density lipoprotein particle. Circ. Res. 114: 193-204.
15. Damiano, M. G., R. K. Mutharasan, S. Tripathy, K. M. McMahon, and C. S. Thaxton. 2013. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv. Drug Deliv. Rev. 65: 649-662.
16. Phillips, M. C. 2014. Molecular mechanisms of cellular cholesterol efflux. J. Biol. Chem. 289: 24020-24029.
17. Zannis, V. I., A. Chroni, and M. Krieger. 2006. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84: 276-294.
18. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
19. Shaw, J. A., A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A. M. Dart. 2008. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103: 1084-1091.
20. Hoang, A., B. G. Drew, H. Low, A. T. Remaley, P. Nestel, B. A. Kingwell, and D. Sviridov. 2012. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur. Heart J. 33: 657-665.
21. Kempen, H. J., M. Gomaraschi, S. E. Bellibas, S. Plassmann, B. Zerler, H. L. Collins, S. J. Adelman, L. Calabresi, and P. L. Wijngaard. 2013. Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. J. Lipid Res. 54: 2341-2353.
22. Thaxton, C. S., W. L. Daniel, D. A. Giljohann, A. D. Thomas, and C. A. Mirkin. 2009. Templated spherical high density lipoprotein nanoparticles. J. Am. Chem. Soc. 131: 1384-1385.
23. Luthi, A. J., H. Zhang, D. Kim, D. A. Giljohann, C. A. Mirkin, and C. S. Thaxton. 2012. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano. 6: 276-285.
24. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
25. Davidson, W. S., W. V. Rodrigueza, S. Lund-Katz, W. J. Johnson, G. H. Rothblat, and M. C. Phillips. 1995. Effects of acceptor particle size on the efflux of cellular free cholesterol. J. Biol. Chem. 270: 17106-17113.
26. Jue, R., J. M. Lambert, L. R. Pierce, and R. R. Traut. 1978. Addition of sulfhydryl-groups to escherichia-coli ribosomes by protein modification with 2-iminothiolane (methyl 4-mercaptobutyrimidate). Biochemistry. 17: 5399-5406.
27. Phillips, M. C. 2013. New insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolism. J. Lipid Res. 54: 2034-2048.
28. Phillips, M. C., and K. E. Krebs. 1986. Studies of apolipoproteins at the air-water interface. Methods Enzymol. 128: 387-403.
29. Shepherd, J., C. J. Packard, J. M. Stewart, B. D. Vallance, T. D. Lawrie, and H. G. Morgan. 1980. The relationship between the cholesterol content and subfraction distribution of plasma highdensity lipoproteins. Clin. Chim. Acta. 101: 57-62.
30. Chen, C. H., and S. G. Engel. 1990. The susceptibility of membrane vesicles to interaction with ethanol. Chem. Phys. Lipids. 52: 179-187.
31. Touitou, E., N. Dayan, L. Bergelson, B. Godin, and M. Eliaz. 2000. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release. 65: 403-418.
32. Sweeney, S. F., G. H. Woehrle, and J. E. Hutchison. 2006. Rapid purification and size separation of gold nanoparticles via diafiltration. J. Am. Chem. Soc. 128: 3190-3197.
33. Daniel, M.-C., and D. Astruc. 2004. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications towards biology, catalysis, and nanotechnology. Chem. Rev. 104: 293-346.
34. Vaughan, A. M., and J. F. Oram. 2006. ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J. Lipid Res. 47: 2433-2443.
35. Vickers, K. C., B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley. 2011. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13: 423-433.
36. Jian, B., M. de la Llera-Moya, Y. Ji, N. Wang, M. C. Phillips, J. B. Swaney, A. R. Tall, and G. H. Rothblat. 1998. Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J. Biol. Chem. 273: 5599-5606.
37. Zhang, X., R. Goncalves, and D. M. Mosser. 2008. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. 83: 14.1.1-14.1.14.
38. Huang, C., and J. T. Mason. 1978. Geometric packing constraints in egg phosphatidylcholine vesicles. Proc. Natl. Acad. Sci. USA. 75: 308-310.
39. Cho, E. J., H. Holback, K. C. Liu, S. A. Abouelmagd, J. Park, and Y. Yeo. 2013. Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol. Pharm. 10: 2093-2110.
40. Lyssenko, N. N., M. Nickel, C. Tang, and M. C. Phillips. 2013. Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability. FASEB J. 27: 2880-2892.
41. Rosenson, R. S., H. B. Brewer, Jr., M. J. Chapman, S. Fazio, M. M. Hussain, A. Kontush, R. M. Krauss, J. D. Otvos, A. T. Remaley, and E. J. Schaefer. 2011. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57: 392-410.
42. Adorni, M. P., F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. C. Phillips, and G. H. Rothblat. 2007. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48: 2453-2462.
43. Okuhira, K., M. Tsujita, Y. Yamauchi, S. Abe-Dohmae, K. Kato, T. Handa, and S. Yokoyama. 2004. Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL. J. Lipid Res. 45: 645-652.
44. Favari, E., I. Zanotti, F. Zimetti, N. Ronda, F. Bernini, and G. H. Rothblat. 2004. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler. Thromb. Vasc. Biol. 24: 2345-2350.
45. Tardif, J. C., C. M. Ballantyne, P. Barter, J. L. Dasseux, Z. A. Fayad, M. C. Guertin, J. J. Kastelein, C. Keyserling, H. Klepp, W. Koenig, et al.; Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. 2014. Effects of the highdensity lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur. Heart J. 35: 3277-3286.
46. Diditchenko, S., A. Gille, I. Pragst, D. Stadler, M. Waelchli, R. Hamilton, A. Leis, and S. D. Wright. 2013. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33: 2202-2211.
47. Gille, A., R. Easton, D. D'Andrea, S. D. Wright, and C. L. Shear. 2014. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler. Thromb. Vasc. Biol. 34: 2106-2114.
48. Haghpassand, M., P. A. Bourassa, O. L. Francon, and R. J. Aiello. 2001. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 108: 1315-1320.
49. Bi, X., X. Zhu, M. Duong, E. Y. Boudyguina, M. D. Wilson, A. K. Gebre, and J. S. Parks. 2013. Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis. Arterioscler. Thromb. Vasc. Biol. 33: 2288-2296.
50. Sparks, D. L., and M. C. Phillips. 1992. Quantitative measurement of lipoprotein surface charge by agarose gel electrophoresis. J. Lipid Res. 33: 123-130.
51. Huang, R., R. A. Silva, W. G. Jerome, A. Kontush, M. J. Chapman, L. K. Curtiss, T. J. Hodges, and W. S. Davidson. 2011. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat. Struct. Mol. Biol. 18: 416-422.
52. Favari, E., L. Calabresi, M. P. Adorni, W. Jessup, S. Simonelli, G. Franceschini, and F. Bernini. 2009. Small discoidal pre-β1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry. 48: 11067-11074.
53. Wang, X., H. L. Collins, M. Ranalletta, I. V. Fuki, J. T. Billheimer, G. H. Rothblat, A. R. Tall, and D. J. Rader. 2007. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 117: 2216-2224.
54. Mulder, W. J., F. A. Jaffer, Z. A. Fayad, and M. Nahrendorf. 2014. Imaging and nanomedicine in inflammatory atherosclerosis. Sci. Transl. Med. 6: 239sr1.
55. Rye, K. A., and P. J. Barter. 2014. Cardioprotective functions of HDLs. J. Lipid Res. 55: 168-179.
56. Zhu, X., M. M. Westcott, X. Bi, M. Liu, K. M. Gowdy, J. Seo, Q. Cao, A. K. Gebre, M. B. Fessler, E. M. Hiltbold, et al. 2012. Myeloid cellspecific ABCA1 deletion protects mice from bacterial infection. Circ. Res. 111: 1398-1409.
57. Liu, M., J. Seo, J. Allegood, X. Bi, X. Zhu, E. Boudyguina, A. K. Gebre, D. Avni, D. Shah, M. G. Sorci-Thomas, et al. 2014. Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein. J. Biol. Chem. 289: 2801-2814.
58. McMahon, K. M., and C. S. Thaxton. 2014. High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin. Drug Deliv. 11: 231-247.